Request for Proposal (RFP) Notice: Medication Discovery Using Rate Relapse Models

Notice Number: NOT-DA-14-039

Key Dates
Release Date: January 22, 2014

Related Announcements
None

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) will solicit proposals from qualified organizations having in-house capability to develop methodologies and to perform in vivo rodent behavioral pharmacology for other drug dependence disorders, using drug self-administration reinstatement models. A solicitation will be released through the Federal Business Opportunities website (URL: https://www.fbo.gov/). The RFP will be released on or about February 4, 2014 and proposals will be due approximately 45 days thereafter.

Research Initiative Details

The objectives of this contract are to determine the in vivo efficacy of novel compounds in animal models of relapse. This includes the following tests in animals trained to self-administer cocaine: (1) the ability of test compound to block footshock or other stress-induced reinstatement of responding after a period of experimental extinction; (2) the ability of a test compound to block cocaine-priming-induced reinstatement of responding after a period of extinction; and (3) the ability of a test compound to block the effects of a conditioned cue (previously paired with cocaine) to reinstate responding for cocaine after a period of extinction.

Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess a Drug Enforcement Agency (DEA) Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule I controlled substances.

Inquiries

Please direct all inquiries to:

Jeffrey Schmidt
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6677
Email: schmidtjr@mail.nih.gov